Argenica Therapeutics Limited (ASX:AGN) is developing novel neuroprotective therapeutics to reduce brain damage after stroke and other devastating brain injuries, focused on the clinical development of its lead drug candidate ARG-007. Argenica has reached key milestones in the development of ARG-007. In the Phase 1 trial, ARG-007 demonstrated safety and tolerability across all tested doses, with no serious adverse events observed in healthy human subjects.
In Phase 2, ARG-007 is being evaluated in ischaemic stroke patients. The Data Safety Monitoring Board (DSMB) recently reviewed safety data from the first 23 patients, reporting no serious adverse effects and recommending the trial continue without modification. Currently, 47% of the targeted 92 patients have been dosed, and all 10 hospital sites are fully operational.
Learn more on the Argenica website.
